EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE
PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO BIOLOGIC
DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (SELECT-PSA-2)

a 2020

EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (SELECT-PSA-2)

GENOVESE, M. C., A. LERTRATANAKUL, J. ANDERSON, K. PAPP, W. TILLETT et. al.

Basic information

Original name

EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (SELECT-PSA-2)

Authors

GENOVESE, M. C., A. LERTRATANAKUL, J. ANDERSON, K. PAPP, W. TILLETT, F. VAN DEN BOSCHC, S. TSUJI, Eva DOKOUPILOVÁ (203 Czech Republic, belonging to the institution), M. KEISERMAN, X. WANG, S. ZHONG, P. ZUEGER, A. PANGAN and P. J. MEASE

Edition

2020

Other information

Language

English

Type of outcome

Konferenční abstrakt

Field of Study

30104 Pharmacology and pharmacy

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

RIV identification code

RIV/00216224:14160/20:00118263

Organization unit

Faculty of Pharmacy

DOI

http://dx.doi.org/10.1136/annrheumdis-2020-eular.1229

UT WoS

000555905000222

Keywords in English

efficacy; safety; upadacitinib; patients; active; psoriatic; arthritis; biological disease;

Abstract

V originále

Upadacitinib (UPA) is an oral, reversible, JAK inhibitor approved for treatment of moderate to severe rheumatoid arthritis (RA) and currently under evaluation for treatment of psoriatic arthritis (PsA).

Citovat

GENOVESE, M. C., A. LERTRATANAKUL, J. ANDERSON, K. PAPP, W. TILLETT, F. VAN DEN BOSCHC, S. TSUJI, Eva DOKOUPILOVÁ, M. KEISERMAN, X. WANG, S. ZHONG, P. ZUEGER, A. PANGAN and P. J. MEASE. EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (SELECT-PSA-2). 2020. Available from: https://dx.doi.org/10.1136/annrheumdis-2020-eular.1229.

@proceedings{1746217,
   author = {Genovese, M. C. and Lertratanakul, A. and Anderson, J. and Papp, K. and Tillett, W. and Van den Boschc, F. and Tsuji, S. and Dokoupilová, Eva and Keiserman, M. and Wang, X. and Zhong, S. and Zueger, P. and Pangan, A. and Mease, P. J.},
   doi = {http://dx.doi.org/10.1136/annrheumdis-2020-eular.1229},
   keywords = {efficacy; safety; upadacitinib; patients; active; psoriatic; arthritis; biological disease;},
   language = {eng},
   title = {EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (SELECT-PSA-2)},
   url = {https://ard.bmj.com/content/79/Suppl_1/139},
   year = {2020}
}

TY  - CONF
ID  - 1746217
AU  - Genovese, M. C. - Lertratanakul, A. - Anderson, J. - Papp, K. - Tillett, W. - Van den Boschc, F. - Tsuji, S. - Dokoupilová, Eva - Keiserman, M. - Wang, X. - Zhong, S. - Zueger, P. - Pangan, A. - Mease, P. J.
PY  - 2020
TI  - EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (SELECT-PSA-2)
KW  - efficacy
KW  - safety
KW  - upadacitinib
KW  - patients
KW  - active
KW  - psoriatic
KW  - arthritis
KW  - biological disease;
UR  - https://ard.bmj.com/content/79/Suppl_1/139
N2  - Upadacitinib (UPA) is an oral, reversible, JAK inhibitor approved for treatment of moderate to severe rheumatoid arthritis (RA) and currently under evaluation for treatment of psoriatic arthritis (PsA).
ER  -

GENOVESE, M. C., A. LERTRATANAKUL, J. ANDERSON, K. PAPP, W. TILLETT, F. VAN DEN BOSCHC, S. TSUJI, Eva DOKOUPILOVÁ, M. KEISERMAN, X. WANG, S. ZHONG, P. ZUEGER, A. PANGAN and P. J. MEASE. \textit{EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (SELECT-PSA-2)}. 2020. Available from: https://dx.doi.org/10.1136/annrheumdis-2020-eular.1229.

Detailed Information on Publication Record